Navigation Links
Abaxis Veterinary Reference Laboratories Now Offering Quantitative Lyme Test

UNION CITY, Calif., Dec. 27, 2011 /PRNewswire/ -- Abaxis, Inc. (NasdaqGS: ABAX), a medical products company manufacturing point of care instrumentation and consumables to the medical, research and veterinary markets, announced today its Abaxis Veterinary Reference Laboratories (AVRL) Division, based in Olathe, Kansas, is now offering a quantitative antibody test for canine Lyme disease. The new canine Lyme test invented and developed by Abaxis, Inc., measures a combination of antibodies to peptides which mimic certain antigens of the Borrelia burgdorferi spirochete. These antibodies are not found in vaccinated or non-infected patients.

Dr. Kenneth Aron, Chief Technology Officer at Abaxis, commented, "We have utilized advances in peptide chemistry and immunology to design a robust laboratory-based test that can distinguish an active Lyme infection from immunity based on vaccination. These advances allow a definitive diagnosis which is required for reference laboratory performed confirmation test."

The new quantitative Lyme test can be used as a standalone diagnostic test to determine infection status or efficacy of treatment. It can also be used as a quantitative confirmation test for the soon to be released VetScan Lyme Rapid Test which is currently under development.

Mark Patterson, President of AVRL added, "The Lyme quantitative antibody test is an exciting addition to the more than 500 tests that are already offered at our new, state of the art facility. It is also a great example of how the Abaxis point-of-care products are complemented by the full service laboratory that we have developed. The Lyme quantitative antibody test is the first of what we expect to be many new and unique assays for the veterinary community."

About Abaxis Abaxis develops, manufactures, markets and sells portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements.  The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients.  The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples.  The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.  The veterinary business also provides to the animal health and research market a line of hematology instruments for point-of-care complete blood counts (CBC), a specialty instrument to screen for and detect clotting disorders and to measure equine fibrinogen levels, a handheld instrument for the rapid assessment of certain critical care tests and rapid point-of-care tests for Heartworm infections in dogs, Parvovirus and Giardia.  Abaxis, through its AVRL Division, provides routine laboratory testing as well as specialty testing for veterinarians nationwide.  This state-of-the-art commercial laboratory will be the hub of the Abaxis Veterinary Reference Laboratories (AVRL).

This press release includes, statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Abaxis' cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations.  Abaxis claims the protection of the safe-harbor for forward-looking statements contained in the Reform Act.  These forward-looking statements are often characterized by the terms "may," "believes," "projects," "expects," "anticipates," or words of similar import, and do not reflect historical facts.  Specific forward-looking statements contained in this press release or in Abaxis' conference call may be affected by risks and uncertainties, including, but not limited to, those related to losses or system failures with respect to Abaxis' facilities or manufacturing operations, fluctuations in quarterly operating results, dependence on sole suppliers, the market acceptance of Abaxis' products, the continuing development of its products and the Abaxis Veterinary Reference Laboratories, required United States Food and Drug Administration clearance and other government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Abaxis' intellectual property or claims of infringement of intellectual property asserted by third parties, risks related to condition of the United States economy and other risks detailed under "Risk Factors" in Abaxis' Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2011 and Abaxis' other periodic reports filed from time to time with the United States Securities and Exchange Commission.  Forward-looking statements speak only as of the date the statements were made.  Abaxis does not undertake and specifically disclaims any obligation to update any forward-looking statements.Contact:

Clint Severson

Lytham Partners, LLCChief Executive Officer

Joe Dorame, Joe Diaz & Robert BlumABAXIS, Inc.


SOURCE Abaxis, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abaxis Animal Health Announces the Addition of a Feline Heartworm Application to the Rapid Diagnostics Product Line
2. Abaxis, Inc. to Present at the 23rd Annual Piper Jaffray Health Care Conference
3. Abaxis, Inc. to Present at Stephens, Inc. 2011 Fall Investment Conference
4. Abaxis, Inc. to Present at Sidoti & Companys New York II Emerging Growth Institutional Investor Forum
5. Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012
6. Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011
7. Abaxis, Inc. to Present at CL Kings 9th Annual Best Ideas Conference 2011
8. Abaxis to Present at 2011 Morgan Stanley Global Healthcare Unplugged Conference
9. Abaxis Announces Stock Repurchase Program
10. Abaxis Reports Financial Performance for the First Quarter of Fiscal 2012
11. Abaxis to Report First Quarter Fiscal Year 2012 Financial Results Thursday, July 28, 2011
Post Your Comments:
(Date:11/30/2015)... Booth #4303 – The Imaging Components business of ... broader array of products in a new booth (#4303) at ... North America in Chicago ... X-ray components "At the Heart of Imaging." Products will include ... Varian,s Claymount brand, and computer-aided diagnostic software from MeVis as ...
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... SHELTON, Connecticut , November 30, 2015 ... Kentucky Breast Care has entered into a ... women,s healthcare practice. This will allow Kentucky Breast Care ... and offer exceptional care for their patients. ... Kentucky Breast Care has entered into a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... 30, 2015 , ... The recently published 32nd Annual Report ... reveals that in 2014, someone called a poison center about every 11 seconds. ... were human exposure cases. , The American Association of Poison Control Centers (AAPCC) ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... as their exclusive channel partner for the Nutraceutical Specialties products into oral solid ... US, effective immediately. , “We are pleased to announce our expanded distribution ...
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... – Kreithen”), one of the leading plastic surgery practices in Florida, is proud ... chosen to consult for surgical innovations giant Ethicon Inc., a Johnson & Johnson ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra Medical, ... Matrix Surgical Mesh technology for soft tissue repair in the US via Insightra’s ... long-term resorbable surgical mesh intended to support and reinforce soft tissue for 6-9 ...
Breaking Medicine News(10 mins):